Efinopegdutide is a promising biomedicine designed to target the treatment of obesity and type 2 diabetes. Through its potent agonist activity on the glucagon-like peptide 1 receptor, it promotes weight loss by reducing appetite and increasing feelings of fullness. Additionally, Efinopegdutide improves glycemic control by regulating insulin secretion and glucose metabolism.
CAT# | R2023 |
CAS | 2055640-93-0 |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
In 1979, GOLDSTEIN et al. extracted an opioid-active 17 peptide from the pituitary of pigs and named it dynorphi ...
Obtustatin isolated from the venom of the Vipera lebetina obtusa viper is a highly potent integrin α1β1 inhibito ...
Signal peptides stimulate matrix protein production in general and collagen synthesis in specific. They may be accomplished b ...
NF-кB activator 1, named Act1, is a 60-kDa (574-aa) polypeptide. Based on its interaction with IKKγ, Act1can be ...
Corticotropin-releasing factor (CRF) is a 41 amino acid peptide that is an important hormone in the hypothalamic ...